The University Hospital of North Norway or UNN is a hospital and health trust. UNN is a university hospital for the region which includes the counties of Nordland, Troms and Finnmark. It is part of the Northern Norway Regional Health Authority. Its service area has a combined population of 465,000.

During the past decade, Universitetssykehuset Nord-Norge conducted 31 clinical trials. In the 10-year time frame, 31 clinical trials started and 8 clinical trials were completed, i.e. on average, 25.8% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 4 clinical trials were completed. i.e. 22.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitetssykehuset Nord-Norge" #1 sponsor was "Boehringer Ingelheim" with 8 trials, followed by "Oslo University Hospital" with 6 trials sponsored, "Janssen Research & Development, LLC" with 3 trials sponsored, "Diakonhjemmet Hospital" with 2 trials sponsored and "Haukeland University Hospital" with 2 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitetssykehuset Nord-Norge" #1 collaborator was "University Hospital of North Norway" with 5 trials as a collaborator, "Haukeland University Hospital" with 4 trials as a collaborator, "Helse Stavanger HF" with 4 trials as a collaborator, "Nordlandssykehuset HF" with 4 trials as a collaborator and "South-Eastern Norway Regional Health Authority" with 4 trials as a collaborator. Other collaborators include 80 different institutions and companies that were collaborators in the rest 70 trials.

According to Clinical.Site data, the most researched conditions in "Universitetssykehuset Nord-Norge" are "Crohn's Disease" (3 trials), "Amyotrophic Lateral Sclerosis" (2 trials), "Aneurysmal Subarachnoid Hemorrhage" (2 trials), "Atrial Fibrillation" (2 trials) and "Cancer" (2 trials). Many other conditions were trialed in "Universitetssykehuset Nord-Norge" in a lesser frequency.

Most popular intervention types in "Universitetssykehuset Nord-Norge" are "Drug" (25 trials), "Other" (5 trials), "Biological" (4 trials), "Device" (3 trials) and "Dietary Supplement" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Atezolizumab" (2 trials), "EH301 (Nicotinamide Riboside/Pterostilbene)" (2 trials), "Empagliflozin" (2 trials) and "Golimumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Universitetssykehuset Nord-Norge" are 39 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Universitetssykehuset Nord-Norge". undefined are not yet recruiting, 17 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Universitetssykehuset Nord-Norge, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Universitetssykehuset Nord-Norge, 0 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 4 trials that are defined as “Not Applicable".

Universitetssykehuset Nord-Norge has several departments that took part in Clinical trials: "Med avd B, Hematologisk seksjon, Universitetssykehuset Nord Norge" - 2 trials